Synchron has secured $200 million to fast-track pivotal trials and gear up for the commercial release of its Stentrode brain-computer interface (BCI) system. BCIs are devices designed to read and interpret brain signals to enable actions like hands-free control of digital gadgets.
BCI devices vary significantly in design and implantation methods. Elon Musk’s Neuralink involves implanting a device by removing part of the skull. In contrast, Synchron’s Stentrode is inserted through a catheter procedure, which is less invasive.
Each method involves a trade-off between surgical invasiveness and the quality of brain signal captured. Synchron's first-generation Stentrode features 16 electrodes, while Neuralink’s N1 implant includes 1,024 electrodes.
“Synchron’s first-generation Stentrode device has 16 electrodes, compared with 1,024 electrodes for Neuralink’s N1 Implant, but it can still enable severely paralyzed people to control personal devices.”
Synchron aims to leverage the advantages of its current device while addressing its limitations over time. The Series D funding will also support development of a next-generation, transcatheter high-channel whole-brain interface.
Artificial intelligence plays a key role in Synchron’s plans. The company is expanding its AI team in New York City, focusing on training models to interpret brain data and decode thoughts in real time.
“Synchron’s goal is to decode thought in real time.”
Backed by $200 million, Synchron is advancing less invasive BCI technology and harnessing AI to enable real-time thought decoding, aiming to transform control options for paralyzed individuals.